Research programme: Alzheimer's disease therapeutics - Memory PharmaceuticalsAlternative Names: MEM 1145
Latest Information Update: 14 Mar 2008
At a glance
- Originator Memory Pharmaceuticals
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Alzheimer's disease; Mild cognitive impairment
Most Recent Events
- 18 Oct 2002 Preclinical trials in Mild cognitive impairment in USA (unspecified route)
- 18 Oct 2002 Preclinical trials in Alzheimer's disease in USA (unspecified route)